8 completed, 1 recruiting, 1 terminated, 1 unknown. 12 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 12 | Completed 8, Recruiting 1, Terminated 1, Unknown 1, Withdrawn 1 |
| Phase 2 | 2 | Completed 2 |
Follow BNT162b2: new trials by email Literature Review of BNT162b2 trials Research Report on BNT162b2
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of COVID-19 Vaccine(s) in Children and Adults BNT162b2 - COVID-19 Vaccines | Phase 3 | Recruiting | BioNTech SE | 700 | 2026-08-31 | 2026-09-28 |
| Evaluation of COVID-19 Vaccines Given as a Booster in Healthy Adults in Indonesia (MIACoV Indonesia) Pfizer-BioNTech Standard dose, AstraZeneca Standard dose, Pfizer-BioNTech Fractional dose - COVID-19 | Phase 3 | Withdrawn | Murdoch Childrens Research Institute | 2024-04-01 | 2024-03-22 | |
| Evaluation of Full Versus Fractional Dose of COVID-19 Vaccine Given as a Booster for the Prevention of COVID-19 in Adults in Mongolia. Tozinameran - Standard Dose, Tozinameran - Fractional Dose - COVID-19 | Phase 3 | Completed | Murdoch Childrens Research Institute | 601 | 2022-05-27 | 2026-03-24 |
| Evaluation of Full Versus Fractional Doses of COVID-19 Vaccines Given as a Booster in Adults in Australia - Mongolia, Indonesia, Australia Coronavirus (MIACoV). Tozinameran - Standard dose, Tozinameran - fractional dose, Elasomeran - standard dose - COVID-19 | Phase 3 | Terminated | Murdoch Childrens Research Institute | 13 | 2022-05-02 | 2024-12-16 |
| Safety and Immunogenicity of BNT162b2 Coadministered With SIIV in Adults 18 Through 64 Years of Age BNT162b2, Placebo, Seasonal Inactivated Influenza Vaccine - SARS-CoV-2 Infection, COVID-19 | Phase 3 | Completed | BioNTech SE | 1134 | 2022-04-20 | 2024-06-12 |
| Immunogenicity and Reactogenicity Following a Booster Dose of COVID-19 mRNA Vaccine (Pfizer-BioNtech) and Two Adjuvanted Sub-unit Vaccines (SP/GSK) Administered in Adults Who Received 2 Doses of Pfizer-BioNTech mRNA Vaccine as a Primary Vaccination BNT162b2, CoV2 preS dTM adjuvanted vaccine (D614), Sanofi/GSK, CoV2 preS dTM adjuvanted vaccine (B.1.351), Sanofi/GSK - COVID-19, Vaccine Reaction | Phase 3 | Unknown | Assistance Publique - Hôpitaux de Paris | 247 | 2021-12-08 | 2022-07-11 |
| To Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of BNT162b2 Boosting Strategies Against COVID-19 in Participants ≥12 Years of Age. BNT162b2, Placebo, BNT162b2 OMI - SARS-CoV-2 Infection, COVID-19 | Phase 3 | Completed | BioNTech SE | 16372 | 2021-07-01 | 2025-11-10 |
| Safety and Immunogenicity Study of 20vPnC When Coadministered With a Booster Dose of BNT162b2 20-valent pneumococcal conjugate vaccine (20vPnC), BNT162b2, Saline - Pneumococcal Disease, COVID-19 | Phase 3 | Completed | Pfizer | 570 | 2021-05-20 | 2022-12-14 |
| A Study to Evaluate Safety, Tolerability, & Immunogenicity of Multiple Formulations of BNT162b2 Against COVID-19 in Healthy Adults BNT162b2 - SARS-CoV-2 Infection, COVID-19 | Phase 3 | Completed | BioNTech SE | 629 | 2021-04-01 | 2022-12-23 |
| To Evaluate the Safety, Tolerability, and Immunogenicity of BNT162b2 Against COVID-19 in Healthy Pregnant Women 18 Years of Age and Older BNT162b2, Placebo - SARS-CoV-2 Infection, COVID-19 | Phase 2 / Phase 3 | Completed | BioNTech SE | 726 | 2021-02-16 | 2024-12-06 |
| A Phase 3 Study to Evaluate the Safety, Tolerability, and Immunogenicity of Multiple Production Lots and Dose Levels of BNT162b2 RNA-Based COVID-19 Vaccines Against COVID-19 in Healthy Participants BNT162b2, BNT162b2.B.1.351 - SARS-CoV-2 Infection, COVID-19 | Phase 3 | Completed | BioNTech SE | 1574 | 2021-02-15 | 2022-12-22 |
| Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals BNT162b1, BNT162b2, Placebo - SARS-CoV-2 Infection, COVID-19 | Phase 2 / Phase 3 | Completed | BioNTech SE | 46969 | 2020-04-29 | 2026-03-25 |
COVID-19 (12) · Coronavirus Infections (6) · Coronaviridae Infections (1) · Infections (1) · Lung Diseases (1) · Nidovirales Infections (1) · Pneumococcal Infections (1) · Pneumonia (1) · Pneumonia, Viral (1) · RNA Virus Infections (1) · Respiratory Tract Diseases (1) · Respiratory Tract Infections (1) · Virus Diseases (1)
BioNTech SE (7) · Murdoch Childrens Research Institute (3) · Assistance Publique - Hôpitaux de Paris (1) · Pfizer (1)
United States (7) · Brazil (3) · South Africa (3) · Australia (2) · Germany (2) · Argentina (1) · France (1) · Indonesia (1) · Israel (1) · Mongolia (1) · New Zealand (1) · Spain (1) · Turkey (Türkiye) (1) · United Kingdom (1)
Eddy Fadlyana, Dr (1) · Kim Mulholland, MD (1) · Kim Mulholland, MD/Prof (1) · Tsetsegsaikhan Batmunkh, MD (1)
PMID 32785213, PMID 33053279, PMID 33301246, PMID 33524990, PMID 34043894, PMID 34525277, PMID 35131133, PMID 35316227, PMID 35320659, PMID 35472295, PMID 35473709, PMID 35739094, PMID 35792746, PMID 36055877, PMID 36652353, PMID 37244809, PMID 37527039, PMID 37698774, PMID 38012751, PMID 38357398, PMID 39197299, PMID 40237463, PMID 40396505, PMID 41072276, PMID 41560517, PMID 41948336, PMID 42501282